Expert: Anastasios Stathis, Oncology Institute of Southern Switzerland, Bellinzona, CH
Questions:
1-How drug-drug interactions can be defined?
2-How frequent they are?
3-Can you make some examples with new drugs approved for lymphoid malignancies?
4-Do all new drugs have the same risk of interactions?
5-What is the best management?
